<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Editas Medicine Inc — News on 6ix</title>
<link>https://6ix.com/company/editas-medicine-inc</link>
<description>Latest news and press releases for Editas Medicine Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/editas-medicine-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835617678dffbe2df0ee6e5.webp</url>
<title>Editas Medicine Inc</title>
<link>https://6ix.com/company/editas-medicine-inc</link>
</image>
<item>
<title>Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences</guid>
<pubDate>Mon, 27 Apr 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing</description>
</item>
<item>
<title>Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-us-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crisprcas9-interference</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-us-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crisprcas9-interference</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing</description>
</item>
<item>
<title>Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-fourth-quarter-and-full-year-2025-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-fourth-quarter-and-full-year-2025-results-and-business-updates</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing</description>
</item>
<item>
<title>Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies</title>
<link>https://6ix.com/company/editas-medicine-inc/news/cassidy-bio-launches-with-the-goal-to-develop-safer-more-scalable-gene-editing-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/cassidy-bio-launches-with-the-goal-to-develop-safer-more-scalable-gene-editing-therapies</guid>
<pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
<description>TEL AVIV, Israel, November 20, 2025--Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies.</description>
</item>
<item>
<title>Editas Medicine Announces Third Quarter 2025 Results and Business Updates</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-third-quarter-2025-results-and-business-updates-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-third-quarter-2025-results-and-business-updates-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as</description>
</item>
<item>
<title>Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-edit-401-poster-presentation-american-heart-association-aha</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-edit-401-poster-presentation-american-heart-association-aha</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing</description>
</item>
<item>
<title>Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-vivo-proof-concept-data-edit-401-european-society-gene-and</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-vivo-proof-concept-data-edit-401-european-society-gene-and</guid>
<pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
<description>Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models CAMBRIDGE, Mass., Oct. 09,</description>
</item>
<item>
<title>Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-edit-401-oral-presentation-european-society-gene-and-cell</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-edit-401-oral-presentation-european-society-gene-and-cell</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing</description>
</item>
<item>
<title>Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-nominates-edit-401-ldlr-targeted-medicine-lead-vivo-development</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-nominates-edit-401-ldlr-targeted-medicine-lead-vivo-development</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong</description>
</item>
<item>
<title>Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-host-webinar-announcing-lead-vivo-development-candidate-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-host-webinar-announcing-lead-vivo-development-candidate-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing</description>
</item>
<item>
<title>Editas Medicine to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-participate-upcoming-investor-conferences-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-participate-upcoming-investor-conferences-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing</description>
</item>
<item>
<title>Editas Medicine Announces Second Quarter 2025 Results and Business Updates</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-second-quarter-2025-results-and-business-updates-2025-08-12</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-second-quarter-2025-results-and-business-updates-2025-08-12</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA</description>
</item>
<item>
<title>Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-proprietary-targeted-lipid-nanoparticle-delivery-non-human</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-proprietary-targeted-lipid-nanoparticle-delivery-non-human</guid>
<pubDate>Thu, 12 Jun 2025 04:00:00 GMT</pubDate>
<description>Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a</description>
</item>
<item>
<title>Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-present-vivo-hsc-delivery-editing-and-biodistribution-data-european</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-present-vivo-hsc-delivery-editing-and-biodistribution-data-european</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates</description>
</item>
<item>
<title>Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-new-vivo-data-highlighting-potential-editas-gene-upregulation</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-new-vivo-data-highlighting-potential-editas-gene-upregulation</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to</description>
</item>
<item>
<title>Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-new-vivo-proof-concept-data-undisclosed-liver-target-american</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-reports-new-vivo-proof-concept-data-undisclosed-liver-target-american</guid>
<pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
<description>In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice</description>
</item>
<item>
<title>Editas Medicine Announces First Quarter 2025 Results and Business Updates</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-first-quarter-2025-results-and-business-updates-2025-05-12</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-first-quarter-2025-results-and-business-updates-2025-05-12</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to</description>
</item>
<item>
<title>Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-us-court-appeals-federal-circuit-remands-crispr-patent</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announces-us-court-appeals-federal-circuit-remands-crispr-patent</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S.</description>
</item>
<item>
<title>Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announce-first-quarter-2025-financial-results-and-participate</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-announce-first-quarter-2025-financial-results-and-participate</guid>
<pubDate>Mon, 05 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing</description>
</item>
<item>
<title>Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting</title>
<link>https://6ix.com/company/editas-medicine-inc/news/editas-medicine-present-preclinical-data-demonstrating-progress-development-vivo-gene</link>
<guid isPermaLink="true">https://6ix.com/company/editas-medicine-inc/news/editas-medicine-present-preclinical-data-demonstrating-progress-development-vivo-gene</guid>
<pubDate>Mon, 28 Apr 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five</description>
</item>
</channel>
</rss>